TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05760729

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive testing
Description: Cognitive tests will be carried: MOCA, trail making test, digit symbol substitution, forward and backward digit testing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive testing
Description: Cognitive tests will be carried: MOCA, trail making test, digit symbol substitution, forward and backward digit testing.
Study: NCT05331664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone 1%
Description: Steroid eye drop 4 times per day tapered by one drop weekly for 4 weeks (4/3/2/1 taper) after surgery
Study: NCT05191030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Stress Intervention
Description: Those undergoing the High-Stress will be exposed to a gold-standard laboratory stressor, the Trier Social Stress Test (Kirschbaum et al., 1993), which reliably induces cortisol reactivity in most individuals.
Study: NCT05331664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine 1%
Description: Eye drop daily for 1 week after surgery
Study: NCT05811572

Intervention type: DEVICE
Intervention: measurement of pelvic floor muscle with perinometer
Description: Questions the person's perceptions about low back pain and related disability VAS questions the person's perceptions about low back pain severity
Study: NCT04823533

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic-placebo supplement
Description: A probiotic formulation containing two well-documented probiotic strains. The finished product is a lyophilized powder packaged in single-dose sticks sachets Excipients used were as follows: xylitol, maltodextrin, plum flavor, and malic acid.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic-placebo supplement
Description: A probiotic formulation containing two well-documented probiotic strains. The finished product is a lyophilized powder packaged in single-dose sticks sachets Excipients used were as follows: xylitol, maltodextrin, plum flavor, and malic acid.
Study: NCT06253728

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fiber and protein meal
Description: In the intervention participants are assigned to eat high protein and fiber meal that differ in protein source or structure.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fiber and protein meal
Description: In the intervention participants are assigned to eat high protein and fiber meal that differ in protein source or structure.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fiber and protein meal
Description: In the intervention participants are assigned to eat high protein and fiber meal that differ in protein source or structure.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fiber and protein meal
Description: In the intervention participants are assigned to eat high protein and fiber meal that differ in protein source or structure.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control meal is low fiber and low protein meal.
Study: NCT06628349

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate 90%
Description: Commercially available animal based protein powders
Study: NCT06421818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baitouweng Tang
Description: Baitouweng Decoction is composed of four herbs: Baitouweng, Rhizoma coptidis, Phellodendri huangbai and Qin Pi.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baitouweng Tang
Description: Baitouweng Decoction is composed of four herbs: Baitouweng, Rhizoma coptidis, Phellodendri huangbai and Qin Pi.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baitouweng Tang
Description: Baitouweng Decoction is composed of four herbs: Baitouweng, Rhizoma coptidis, Phellodendri huangbai and Qin Pi.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The same volume and color as Baitouweng Decoction.
Study: NCT06075771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa Levodopa
Description: Patients will receive between one and three tablets per day of 150 mg L-DOPA (administered with 37.5 mg carbidopa) to achieve doses ranging from 150 to 450 mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive between one and three placebo tablets per day matching the Carbidopa Levodopa tablet.
Study: NCT06628349

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate 90%
Description: Commercially available animal based protein powders

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate 90%
Description: Commercially available animal based protein powders

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate 90%
Description: Commercially available animal based protein powders

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate 90%
Description: Commercially available animal based protein powders

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Protein Isolate (90% Protein)
Description: Commercially available plant based protein powders

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Protein Isolate (90% Protein)
Description: Commercially available plant based protein powders

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Protein Isolate (90% Protein)
Description: Commercially available plant based protein powders
Study: NCT04967755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jing-Si-Herbal-Tea
Description: Eligible patients were randomized to receive routine treatment alone based on the Novel Coronavirus Interim Guidelines for Clinical Management of SARS-CoV-2 Infection (Eleventh edition 2021) (control group) or the combination of routine treatment and JSHT (1 drink thrice daily for 7 days) (JSHT group) at the discretion of the attending clinicians. Routine treatment generally consisted of the supportive treatment such as oxygen therapy, antiviral medications and symptomatic therapies. Adherence to the study medications, clinical outcomes, the use of concomitant medications and adverse events were recorded. The following data were collected at admission: demographics, body mass index, smoking history, comorbidities, CURB-65 Score for pneumonia. Hemogram, laboratory testing, chest X-ray, and nucleic acid assays of SARS-CoV-2 were evaluated at admission and after randomization and on 7th day.
Study: NCT05626686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLINY catheter
Description: Subjects using a single use catheter for bladder management at inclusion. During the study period, subjects will use the reusable CLINY catheter for 28 test-days
Study: NCT06497686

Intervention type: DIAGNOSTIC_TEST
Intervention: mesoscale nonlinear optical gigascope
Description: An nonlinear optical microscope with ultra-large field of view and ultra-high resolution.

Intervention type: DIAGNOSTIC_TEST
Intervention: mesoscale nonlinear optical gigascope
Description: An nonlinear optical microscope with ultra-large field of view and ultra-high resolution.
Study: NCT05502848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Cognitive Behavior Therapy
Description: ICBT helps change patterns of thinking (cognitions) and behaviors of psychological distress, including relaxation, stress management, while using ICBT can increase personal tolerance for negative thoughts and negative emotions, help patients reduce negative perception of the disease due to long-term recurrent itching, and break the vicious cycle
Study: NCT04797013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rt-PA
Description: Subjects will be randomized to rhTNK-tPA or rt-PA in a 1:1 ratio.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhTNK-tPA
Description: Subjects will be randomized to rhTNK-tPA or rt-PA in a 1:1 ratio.
Study: NCT05836961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Benazir Nashonuma Program (BNP)
Description: Dietary supplement for pregnant women and lactating mothers during the first six months of lactation:~Maamta is a 75-gram sachet made from peanut butter with 400 kcal of energy~Dietary supplement for children aged 6-23 months:~Wawamum is a lipid-based nutrient supplement consisting of skimmed milk powder, micronutrients, vegetable oil, roasted chickpeas and antioxidants. Wawamum covers the recommended daily dose of most micronutrients and 255 kcal of energy (1/4 of daily energy requirements for children in this age range)~Conditional Cash Transfers (CCT):~This includes stipends of PKR 2000 during pregnancy contingent on three antenatal care visits, consuming SNF, attending awareness sessions on health and nutrition, getting two doses of tetanus toxoid and institutional delivery. After delivery PKR 2000/- for boys and 2500/- for girls are paid as incentives conditioned on getting child's birth registered, routine immunization and consumption of SNF by the child from 6-23 months
Study: NCT04805931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral economics
Description: Tailored behavioral economic text messaging vs. standard text messaging

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral economics
Description: Tailored behavioral economic text messaging vs. standard text messaging
Study: NCT06628349

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Protein Isolate (90% Protein)
Description: Commercially available plant based protein powders

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Protein Isolate (90% Protein)
Description: Commercially available plant based protein powders

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Protein Isolate (90% Protein)
Description: Commercially available plant based protein powders

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Organic Pea Protein Isolate
Description: Commercially available plant based protein powders

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Organic Pea Protein Isolate
Description: Commercially available plant based protein powders

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Organic Pea Protein Isolate
Description: Commercially available plant based protein powders

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Organic Pea Protein Isolate
Description: Commercially available plant based protein powders

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Organic Pea Protein Isolate
Description: Commercially available plant based protein powders

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Organic Pea Protein Isolate
Description: Commercially available plant based protein powders

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo (Water)
Description: Normal drinking water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo (Water)
Description: Normal drinking water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo (Water)
Description: Normal drinking water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo (Water)
Description: Normal drinking water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo (Water)
Description: Normal drinking water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo (Water)
Description: Normal drinking water
Study: NCT06235242

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GT201 injection in combination with teraplizumab injection
Description: GT201 injection in combination with teraplizumab injection for treatment of patients with non-small cell lung cancer
Study: NCT05205967

Intervention type: OTHER
Intervention: MCED
Description: Multi-cancer early detection (MCED) test

Intervention type: OTHER
Intervention: SOC
Description: Standard of care cancer screening
Study: NCT05814601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norepinephrine
Description: norepinephrine at a concentration of 5 mcg/ml is preemptively administered
Study: NCT05718076

Intervention type: PROCEDURE
Intervention: cataract surgery
Description: Phacoemulsification combined trifocal lens implantation

Intervention type: PROCEDURE
Intervention: cataract surgery
Description: Phacoemulsification combined trifocal lens implantation

Intervention type: PROCEDURE
Intervention: cataract surgery
Description: Phacoemulsification combined trifocal lens implantation
Study: NCT05535673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ThisCART19A
Description: In this study, allogeneic anti-CD19 CAR-T cell (ThisCART19A) injection is used to treat patients with refractory or relapsed CD19 positive B cell Lymphoma.
Study: NCT04914130

Intervention type: OTHER
Intervention: Study specific testing procedures
Description: Study specific procedures includes blood sampling, neurocognitive testing, respiratory questionnaire, brain MRI for MRI substudy group, lumbar puncture for MRI substudy group, etc

Intervention type: OTHER
Intervention: Study specific testing procedures
Description: Study specific procedures includes blood sampling, neurocognitive testing, respiratory questionnaire, brain MRI for MRI substudy group, lumbar puncture for MRI substudy group, etc

Intervention type: OTHER
Intervention: Study specific testing procedures
Description: Study specific procedures includes blood sampling, neurocognitive testing, respiratory questionnaire, brain MRI for MRI substudy group, lumbar puncture for MRI substudy group, etc
Study: NCT06497647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulbutiamine
Description: sulbutiamine will be used by oral route 100 mg daily for 1 month and follow up will be done every 1 month till 3 months.~it will be used alone in group B and combined with imipramine in group C
Study: NCT06500182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hippotherapy sessions
Description: Patients benefit from the hippotherapy sessions in additional to continuing to receive traditional care.
Study: NCT06782035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ora-Aid-Oral Wound Dressing
Description: Intended as a physical barrier for temporary protection of oral mucosal tissue and to provide pain relief. This product is a non-eugenol protective material applied to intraoral wounds. Ora-Aid is a new concept of pasting intra-oral patch to protect the affected area such as post implant, extraction, orthodontic, and ulcers. This new concept of pasting intra-oral wound dressing is designed to protect the affected area and aid natural healing.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich fibrin
Description: It has been reported that the use of Platelet-Rich Fibrin (PRF) to cover palatal wounds accelerates healing and reduces postoperative morbidity. Studies have demonstrated that PRF supports key processes in wound healing, such as immunity, angiogenesis, and cellular proliferation. Its use has garnered significant interest, particularly in non-healing wounds and areas left to heal by secondary intention after surgery. Leukocyte and Platelet-Rich Fibrin (L-PRF) is frequently used in periodontal surgical applications. The platelets and growth factors it contains accelerate the healing process and facilitate tissue repair.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Palatal Stent
Description: Palatal stents help prevent complications such as infection or excessive discomfort. These plates are typically customized to fit the patient's palate by taking impressions before the surgery. Once placed, they serve as a barrier, especially during the early stages of healing. Additionally, they may reduce the need for postoperative interventions, such as the use of strong painkillers.
Study: NCT06497686

Intervention type: DIAGNOSTIC_TEST
Intervention: Fluorescence microscope
Description: An optical microscope used to examine the fluorescence signal from stained tissues.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fluorescence microscope
Description: An optical microscope used to examine the fluorescence signal from stained tissues.
Study: NCT06570109

Intervention type: OTHER
Intervention: Frailty
Description: defined as weigh loss (\>4.5 kg in one year), exhaustion, slow gait speed (below 20th percentile for sex and height), weakness (handgrip strength below 20th percentile for sex and BMI), and low physical activity (by the Physical Activity Scale for the Elderly). The presence of three or more out of five criteria is defined as frailty while one to two criteria is prefrailty
Study: NCT06497647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulbutiamine
Description: sulbutiamine will be used by oral route 100 mg daily for 1 month and follow up will be done every 1 month till 3 months.~it will be used alone in group B and combined with imipramine in group C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipramine
Description: imipramine will be used by oral route 25 mg daily for 1 month and follow up will be done every 1 month till 3 months.~it will be used alone in group A and combined with sulbutiamine in group C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipramine
Description: imipramine will be used by oral route 25 mg daily for 1 month and follow up will be done every 1 month till 3 months.~it will be used alone in group A and combined with sulbutiamine in group C
Study: NCT06494904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: All patients will receive 3 pills and will be observed for 2 hours post-study medication administration with repeated COWS at approximately hours 1 and 2. All participants will be given a referral for ongoing MOUD and will be discharged with a prescription for 16 mg daily of buprenorphine daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: All patients will receive 3 pills and will be observed for 2 hours post-study medication administration with repeated COWS at approximately hours 1 and 2. All participants will be given a referral for ongoing MOUD and will be discharged with a prescription for 16 mg daily of buprenorphine daily.
Study: NCT05154214

Intervention type: PROCEDURE
Intervention: Adenotonsillectomy
Description: Removal of tonsils and adenoids
Study: NCT06651554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Platform Intervention
Description: Key features of the digital platform include mental health self-help tools, a customizable safety plan, links to online counseling services, and gamification elements. Youth will be able to access the digital platform as often as they like during their assigned 3-month intervention period.
Study: NCT05836259

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: TN-201
Description: TN-201 is a recombinant adeno-associated virus serotype 9 (AAV9) containing Myosin Binding Protein C (MYBPC3) transgene. It is a single (one-time) intravenous dose.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: TN-201
Description: TN-201 is a recombinant adeno-associated virus serotype 9 (AAV9) containing Myosin Binding Protein C (MYBPC3) transgene. It is a single (one-time) intravenous dose.
Study: NCT05895045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Restorative Vinyasa Yoga

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Restorative Vinyasa Yoga

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Restorative Vinyasa Yoga

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Restorative Vinyasa Yoga
Study: NCT06603831

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patients treated using 3D technology and Patient-Specific Instrumentation
Description: 3D Digital surgery includes:~* 3D Surgical Planning using biomedical engineering software; 3D visualization of the patients anatomy and surgical simulation.~* Use of personalized surgical guides created through additive manufacturing.~* Use of personalized implants created through additive manufacturing.~  3 surgical procedures are studied in this study; radius osteotomy, acetabular arthroplasty and spinal arthrodesis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients treated with conventional surgery, without using 3D technology
Description: Conventional surgery includes:~* 2D planning using TC and x-rays~* Free-hand surgery~* Use of generic, non-personalized implants~  3 surgical procedures are studied in this study; radius osteotomy, acetabular arthroplasty and spinal arthrodesis
Study: NCT04984590

Intervention type: DEVICE
Group type: OTHER
Intervention: IOPCL AMD MAG
Description: The IOPCL MAG (intraocular pseudophakic capsular lens magnifier) consists of a 4.5 mm diameter optic. The central 1.8mm of the anterior surface has a power of 10.0 diopters. This IOPCL MAG will be implanted over an Alcon Model SN60WF or SA60AT intraocular lens to improve near vision.
Study: NCT06596772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB04 (proposed biosimilar to etanercept)
Description: MB04 50 mg/week via subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enbrel (etanercept)
Description: Enbrel 50 mg/week via subcutaneous injection
Study: NCT06656221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab pre-treatment is given intravenously at a dose of 2000mg on Cycle 1 Days 1-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Glofitamab is given intravenously at a dose of 2.5mg on Cycle 1 Day 8. Glofitamab is given intravenously at a dose of 10mg on Cycle 1 Day 15. Glofitamab is given intravenously at a dose of 30mg on Day 1 of Cycles 2-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib is given intravenously at a dose of 1.6 mg/m² on Days 1, 8, and 15 of Cycles 1-12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib is given orally at a dose of 150 mg daily on Days 1-21 of Cycles 1-12.
Study: NCT06649773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noiiglutide Injection
Description: Experimental group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Noiiglutide Placebo
Description: Placebo Comparator group